Literature DB >> 18314283

Microbiology of otitis externa in the secondary care in United Kingdom and antimicrobial sensitivity.

G Ninkovic1, V Dullo, N C Saunders.   

Abstract

INTRODUCTION: Otitis externa is one of the most common conditions seen in the otolaryngology clinics. There are no recently published studies that have looked at the causative pathogens of the otitis externa seen in secondary care in the United Kingdom and their antimicrobial sensitivities. We present results of a prospective study to determine the current bacteriology of the condition.
METHODS: Swabs were taken from the external auditory canals of the patients who presented to the otolaryngology emergency clinic with symptoms of otitis externa. These were analysed using microscopy, culture and sensitivity testing in one laboratory. The samples were cultured on blood agar, chocolate agar, Sabouraud agar, fastidious anaerobes agar with neomycin and staph/strep agar. Antimicrobial sensitivities of isolated pathogens were tested on iso-sensitest and blood agars using the BSAC disc diffusion template program.
RESULTS: The most commonly identified pathogen was Pseudomonas aeruginosa (45.1%), followed by Staphylococcus aureus (9%), anaerobes (6.3%), beta haemolytic Streptococcus group G (2.8%), beta haemolytic Streptococcus group A (1.4%), Streptococcus pneumoniae (0.7%), methicillin resistant S. aureus (0.7%), Candida species (9.7%), Aspergillus species (4.2%) and Absidia corymbifera (0.7%). One hundred percent resistance of Pseudomonas isolates to neomycin, chloramphenicol, trimethoprim and amoxicillin was observed while most were sensitive to ciprofloxacin (100%), polymixin B (100%) and gentamicin (98.5%). S. aureus isolates were sensitive to gentamicin and flucloxacillin (100%). 92.3% were sensitive to neomycin and chloramphenicol. Resistance to penicillin and amoxicillin is observed. All isolates anaerobes were sensitive to metronidazole.
CONCLUSION: Polymixin B, gentamicin or ciprofloxacin topical preparations should be used as first line treatment of otitis externa. If the infection does not settle swab results should be used to guide further treatment.

Entities:  

Mesh:

Year:  2008        PMID: 18314283     DOI: 10.1016/j.anl.2007.09.013

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  7 in total

1.  A study of acute otitis externa at Wellington Hospital, 2007-2011.

Authors:  Rahul Jayakar; James Sanders; Emily Jones
Journal:  Australas Med J       Date:  2014-10-31

2.  Seasonal variation of Pseudomonas aeruginosa in culture positive otitis externa in South East England.

Authors:  A Villedieu; E Papesh; S E Weinberg; L Teare; J Radhakrishnan; W F Elamin
Journal:  Epidemiol Infect       Date:  2018-07-06       Impact factor: 4.434

3.  Otomycosis in Adolescent Patients Referred to the Therapeutic Centers in Babol City, Iran.

Authors:  Keivan Kiakojuri; Ramazan Rajabnia; Bahareh Jalili; Soraya Khafri; Saeid Mahdavi Omran
Journal:  Jundishapur J Microbiol       Date:  2015-05-31       Impact factor: 0.747

4.  [Epidemiological, clinical and therapeutic aspects of otitis externa: about 801 cases].

Authors:  Amana Bathokedeou; Pegbessou Essobozou; Patassi Akouda; Boko Essohanam; Kpémissi Eyawelohn
Journal:  Pan Afr Med J       Date:  2014-02-28

5.  Methicillin-resistant Staphylococcus aureus in acute otitis externa.

Authors:  Maria J Duarte; Elliott D Kozin; Paulo J M Bispo; Andreas H Mitchell; Michael S Gilmore; Aaron K Remenschneider
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2017-11-23

6.  The Impact of using the term "Diabetic Ear" for the patients with Skull Base Osteomyelitis.

Authors:  Abdulaziz S AlEnazi; Salma S Al Sharhan; Laila M Telmesani; Nasser A Aljazan; Bander M Al Qahtani; Mohamed A Lotfy
Journal:  J Family Community Med       Date:  2019 Jan-Apr

7.  Bacterial Otitis Externa in Patients Attending an ENT Clinic in Babol, North of Iran.

Authors:  Keyvan Kiakojuri; Saeid Mahdavi Omran; Bahareh Jalili; Mahmood Hajiahmadi; Meghdad Bagheri; Elaheh Ferdousi Shahandashti; Ramazan Rajabnia
Journal:  Jundishapur J Microbiol       Date:  2016-02-13       Impact factor: 0.747

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.